EyePoint, Inc. reported Q2 2026 financial results and highlighted progress in its DURAVYU clinical programs for retinal diseases. The company anticipates topline data from its pivotal Phase 3 LUGANO trial for wet age-related macular degeneration (wet AMD) in August 2026 and from the LUCIA trial in Q4 2026. Additionally, enrollment completed for Phase 3 diabetic macular edema (DME) trials COMO and CAPRI, with topline data expected in Q4 2027. EyePoint holds $180 million in cash and investments, providing operational funding into late 2027. These developments position DURAVYU as a potential foundational sustained treatment for serious retinal diseases, pending regulatory approval.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
